Sabin's own Sabin Product Development Partnership (PDP) has released updates regarding five Phase 1 clinical trials for two vaccine candidates for human hookworm, one of the most common neglected tropical diseases (NTDs). Since the trials began on a total of 238 volunteers in Washington, D.C. , Gabon and Brazil, their response to the vaccine has been well tolerated without serious adverse events.
"A recent Global Burden of Disease study estimates almost half a billion people are infected with hookworm, indicating that it is one of the most ubiquitous infections of the poor," said Peter Hotez, MD, PhD, president of Sabin, director of the Sabin Vaccine Institute PDP and dean of the National School of Tropical Medicine at Baylor College of Medicine. "A vaccine to combat human hookworm would be an important technological breakthrough in global efforts to prevent serious health issues such as iron-deficiency anemia (IDA). In particular, success in the clinical testing of the human hookworm vaccine in Gabon and Brazil could lead to the development of the first vaccine that specifically targets IDA in low- and middle-income countries, where hookworm infection is widespread."